Skip to main content

Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.

Publication ,  Journal Article
Balevic, SJ; Randell, R; Weiner, D; Beard, C; Schanberg, LE; Hornik, CP; Cohen-Wolkowiez, M; Gonzalez, D; with the CARRA Registry investigators
Published in: Lupus Sci Med
November 2022

OBJECTIVE: Determine the pharmacokinetics (PK) and exposure-response of hydroxychloroquine (HCQ) and desethylhydroxychloroquine (DHCQ) in paediatric SLE (pSLE). METHODS: We conducted an exploratory phase 2, direct-to-family trial. Children enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry with a diagnosis of pSLE were eligible if they were receiving HCQ as standard of care for ≥3 months. Biological samples were collected at up to four visits over a 6-month period. At each visit, plasma was obtained to measure the concentrations of HCQ and DHCQ, as well as cytokines. HCQ and DHCQ plasma PK data were analysed using a population PK modelling approach. RESULTS: Twenty-five subjects provided a total of 88 plasma concentrations for PK analysis. There was a poor linear fit between HCQ concentrations and total body weight (R2=0.03). There was a decline in both interferon (IFN)-alpha and IFN-gamma with higher concentrations of HCQ and DHCQ. Volume of distribution for HCQ in plasma was higher in children compared with published values in adults (73 000 L vs 44 000 L), but clearance values in children were similar to adults. CONCLUSIONS: We report the first population PK model for HCQ and DHCQ in children using data from a novel direct-to-family clinical trial. We observed high interindividual variability in HCQ PK and found that weight-based dosing for HCQ is poorly correlated with drug concentrations, suggesting the need to use therapeutic drug monitoring to individualise dosing. Furthermore, our results suggest that the current weight-based dosing paradigm for HCQ may result in suboptimal drug exposures, particularly for children with obesity. Accordingly, additional studies of HCQ are needed in pSLE to determine the optimal drug concentration and dosing to reduce disease activity and improve outcomes. TRIAL REGISTRATION NUMBER: NCT04358302.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Lupus Sci Med

DOI

ISSN

2053-8790

Publication Date

November 2022

Volume

9

Issue

1

Location

England

Related Subject Headings

  • Lupus Erythematosus, Systemic
  • Hydroxychloroquine
  • Humans
  • Drug Monitoring
  • Child
  • Antirheumatic Agents
  • Adult
  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Balevic, S. J., Randell, R., Weiner, D., Beard, C., Schanberg, L. E., Hornik, C. P., … with the CARRA Registry investigators. (2022). Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. Lupus Sci Med, 9(1). https://doi.org/10.1136/lupus-2022-000811
Balevic, Stephen J., Rachel Randell, Daniel Weiner, Claire Beard, Laura Eve Schanberg, Christoph P. Hornik, Michael Cohen-Wolkowiez, Daniel Gonzalez, and with the CARRA Registry investigators. “Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.Lupus Sci Med 9, no. 1 (November 2022). https://doi.org/10.1136/lupus-2022-000811.
Balevic SJ, Randell R, Weiner D, Beard C, Schanberg LE, Hornik CP, et al. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. Lupus Sci Med. 2022 Nov;9(1).
Balevic, Stephen J., et al. “Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.Lupus Sci Med, vol. 9, no. 1, Nov. 2022. Pubmed, doi:10.1136/lupus-2022-000811.
Balevic SJ, Randell R, Weiner D, Beard C, Schanberg LE, Hornik CP, Cohen-Wolkowiez M, Gonzalez D, with the CARRA Registry investigators. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial. Lupus Sci Med. 2022 Nov;9(1).

Published In

Lupus Sci Med

DOI

ISSN

2053-8790

Publication Date

November 2022

Volume

9

Issue

1

Location

England

Related Subject Headings

  • Lupus Erythematosus, Systemic
  • Hydroxychloroquine
  • Humans
  • Drug Monitoring
  • Child
  • Antirheumatic Agents
  • Adult
  • 3204 Immunology
  • 3202 Clinical sciences